Page last updated: 2024-08-21

indazoles and s 1033

indazoles has been researched along with s 1033 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Robert, C; Sibaud, V	1
Li, J	1
Alcoser, SY; Borgel, S; Bottaro, DP; Chen, AP; Chen, L; Chuaqui, R; Doroshow, JH; Ferry-Galow, KV; Hollingshead, MG; Kinders, RJ; Konaté, MM; Kummar, S; Lawrence, SM; Makhlouf, HR; Miller, SB; Navas, T; Parchment, RE; Rubinstein, L; Srivastava, AK; Subramanian, J; Vilimas, T; Voth, AR; Wilsker, DF	1
Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E	1

Reviews

1 review(s) available for indazoles and s 1033

Article	Year
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles	2013

Article

Year

[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].

Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles

2013

Other Studies

3 other study(ies) available for indazoles and s 1033

Article	Year
[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2016, Nov-25, Volume: 19, Issue:11 Topics: Benzimidazoles; Exons; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Indazoles; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolones; Succinate Dehydrogenase; Sulfonamides	2016
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. Cancer research, 2020, 01-15, Volume: 80, Issue:2 Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Biopsy, Large-Core Needle; Cadherins; Carcinoma; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Indazoles; Male; Mice; Neoplastic Stem Cells; Paclitaxel; Pyrimidines; Sulfonamides; Vimentin; Xenograft Model Antitumor Assays	2020
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan. JAMA network open, 2020, 11-02, Volume: 3, Issue:11 Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States	2020